title: Two cases of successful treatment for severe skin rash induced by vemurafenib following nivolumab therapy without cessation of vemurafenib.
authors.affiliation: Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan.
authors.forename: Satoshi
authors.initials: S
authors.lastname: Tsuboi
authors.affiliation: Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan.
authors.forename: Koji
authors.initials: K
authors.lastname: Yoshino
authors.affiliation: Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan.
authors.forename: Kei
authors.initials: K
authors.lastname: Yamaguchi
authors.affiliation: Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan.
authors.forename: Keisuke
authors.initials: K
authors.lastname: Imafuku
authors.affiliation: Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan.
authors.forename: Kuniaki
authors.initials: K
authors.lastname: Ohara
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D005076:Exanthema / Q000139:chemically induced* / Q000517:prevention & control*; D005260:Female; D005938:Glucocorticoids / Q000627:therapeutic use; D006801:Humans; D008545:Melanoma / Q000188:drug therapy*; D000077594:Nivolumab / Q000008:administration & dosage*; D011239:Prednisolone / Q000627:therapeutic use; D048493:Proto-Oncogene Proteins B-raf; D012878:Skin Neoplasms / Q000188:drug therapy*; D000077484:Vemurafenib / Q000008:administration & dosage* / Q000009:adverse effects
chemical_list: D005938:Glucocorticoids; D000077484:Vemurafenib; D000077594:Nivolumab; D011239:Prednisolone; D048493:Proto-Oncogene Proteins B-raf